Hepatic Cell News
Hepatic Cell News is an online resource covering the top research on hepatocytes and liver diseases.
Activation of RAS/MEK/ERK Signaling Drives Biliary Differentiation in Primary Liver Cancer
[Gut] Researchers used genetically engineered mouse models with liver-specific deletion of tumour suppressors Rb and p53 together with activation of oncogenic Kras to investigate the cell of origin in intrahepatic cholangiocarcinoma.
Sitravatinib Targets TYRO3 to Augment the Anti-Tumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
[Clinical Cancer Research] Scientists investigated the anti-tumor efficacy and immunomodulatory activity of sitravatinib in hepatocellular carcinoma.
Sitravatinib Targets TYRO3 to Augment the Anti-Tumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
[Clinical Cancer Research] Human HCC cell lines and xenograft models were used to explore the anti-tumor activity of sitravatinib. Subcutaneous and orthotopic immunocompetent murine HCC models were used to assess the therapeutic efficacy of sitravatinib and PD-1 blockade combination therapy.
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
[New England Journal of Medicine] In this phase IIb, randomized, placebo-controlled, double-blind trial, investigators assigned patients with MASH who had biopsy-confirmed compensated cirrhosis to receive subcutaneous efruxifermin or placebo.
Targeting HMGB2 Acts As Dual Immunomodulator by Bolstering CD8+ T Cell Function and Inhibiting Tumor Growth in Hepatocellular Carcinoma
[Science Advances] The authors analyzed human and murine single-cell RNA sequencing data and identified the underlying mechanisms of high-mobility group box 2 (HMGB2) promoting HCC progression through dual action on effector T cells and cancer cells, respectively.
NCOA5 Induces Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Ferroptosis
[Cell Death Discovery] Scientists investigated the expression of nuclear receptor coactivator 5 (NCOA5) in HCC, revealing its significant overexpression in tumor tissues compared to healthy liver tissues, as evidenced by analysis of the TCGA dataset and RT-qPCR in patient samples.
New Platinum Derivatives Selectively Cause Double-Strand DNA Breaks and Death in Naïve and Cisplatin-Resistant Cholangiocarcinomas
[Journal of Hepatology] Researchers designed and evaluated two novel compounds, Aurkine 16 and Aurkine 18, for their antitumor effects in both naïve and cisplatin-resistant cholangiocarcinoma cells, cancer-associated fibroblasts, healthy cholangiocytes, and in vivo models.
Phase III Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
[New England Journal of Medicine] In this ongoing phase III, multicenter, randomized, double-blind, placebo-controlled trial, investigators assigned 1197 patients with biopsy-defined metabolic dysfunction–associated steatohepatitis and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks.
A Symbiotic Filamentous Gut Fungus Ameliorates MASH via a Secondary Metabolite-CerS6-Ceramide Axis
[Science] The authors investigated whether gut fungi play a role in host disease and particularly in metabolic dysfunction–associated steatohepatitis (MASH) progression in mouse models.
Bayer Initiates Phase I Study Targeting GPC3 with Actinium-225 Radiopharmaceutical in Patients with Advanced Hepatocellular Carcinoma
[Bayer] Bayer announced the initiation of a Phase I clinical trial with 225Ac-GPC3, an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing glypican-3 (GPC3) in patients with advanced HCC.
FBL Promotes Hepatocellular Carcinoma Tumorigenesis and Progression by Recruiting YY1 to Enhance CAD Gene Expression
[Cell Death & Disease] The authors investigated key epigenetic regulators that contribute to tumorigenesis and progression, providing a theoretical basis for targeted therapy for HCC.
Intra-Hepatic Microbial Heterogeneity in Multifocal Hepatocellular Carcinoma and Its Association with Host Genomic and Transcriptomic Alterations
[Cancer Discovery] Researchers performed multi-omics profiling of 242 HCC tumor nodules and 58 adjacent non-tumor tissues from 58 multifocal HCC patients, revealing heterogeneous microbial communities in multifocal HCC.
The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. We cover areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!